Duvera Lifesciences Profile
Key Indicators
- Authorised Capital ₹ 5.00 M
as on 14-12-2024
- Paid Up Capital ₹ 4.00 M
as on 14-12-2024
- Company Age 8 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue -13.95%
(FY 2020)
- Profit 71.92%
(FY 2020)
- Ebitda 72.05%
(FY 2020)
- Net Worth -18.30%
(FY 2020)
- Total Assets 39.51%
(FY 2020)
About Duvera Lifesciences
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 M and a paid-up capital of Rs 4.00 M, as per Ministry of Corporate Affairs (MCA) records.
Arshi Parvez, Satish Singh, and Piyush Singh serve as directors at the Company.
- CIN/LLPIN
U24230MH2016PTC283770
- Company No.
283770
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
18 Jul 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Duvera Lifesciences Private Limited offer?
Duvera Lifesciences Private Limited offers a wide range of products and services, including Ayurvedic Herbal Syrups & Tonics, Ayurvedic Health Tonic, Multivitamin Tablets & Capsules, Iron Folic Acid Tablet, Herbal Capsules.
Who are the key members and board of directors at Duvera Lifesciences?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arshi Parvez  | Director | 18-Jul-2016 | Current |
| Satish Singh | Director | 24-Nov-2017 | Current |
| Piyush Singh | Director | 24-Nov-2017 | Current |
Financial Performance of Duvera Lifesciences.
Duvera Lifesciences Private Limited, for the financial year ended 2020, experienced significant reduction in revenue, with a 13.95% decrease. The company also saw a substantial improvement in profitability, with a 71.92% increase in profit. The company's net worth observed a substantial decline by a decrease of 18.3%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Duvera Lifesciences?
In 2020, Duvera Lifesciences had a promoter holding of 25.00% and a public holding of 75.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Duvera Lifesciences?
Unlock and access historical data on people associated with Duvera Lifesciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Duvera Lifesciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Duvera Lifesciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
